6533b7dafe1ef96bd126d848
RESEARCH PRODUCT
Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study
A Francesco BartoliA Daniele CavaleriA Tommaso CalloviniA Ilaria RiboldiA Cristina CrocamoB Armando D’agostinoC Giovanni MartinottiD Federico BertoliniD Giovanni OstuzziD Corrado BarbuiA Giuseppe Carr`a Star Network Depot InvestigatorsBarbui CorradoBertolini FedericoBoschello FilippoGastaldon Chiara Maria Angela MazziNos´e MichelaOstuzzi GiovanniPapola DavidePerini GiovanniPiccoli AlbertoPievani MichelaPurgato MariannaRuggeri MirellaTedeschi FedericoTerlizzi Samira And Giulia Turrini (Verona)Caroleo Mariarita Pasquale De FazioMagliocco Fabio And Gaetano Raffaele (Catanzaro)Cavallotti SimoneChirico MargheritaD’agostino ArmandoFerrato FaridaLimosani IvanMastromo DanieleMonzani Emiliano Edoardo Giuseppe OstinelliPorcellana Matteo And Francesco Restaino (Milano) Pasqua Maria AnneseBolognesi SimoneCerretini Massimiliano Alberto De CapuaDebolini Sara Maria Del ZannaFargnoli FrancescoGiannini AlessandraLuccarelli LiviaLucii ClaudioPierantozzi Elisa And Fiorella Tozzi (Siena)Bardicchia FrancescoCardamone GiuseppeFacchi EdvigeMagnani Nadia And Federica Soscia (Grosseto)And Spyridon Zotos (Ferrara) Bruno BiancosinoGiacomin MarzioPompei FrancescoSpano Mariangela And Filippo Zonta (Treviso)Aldo Emanuele BuzziCamilla CallegariCalzolari RobertaIvano CaselliDiurni Marcello Edoardo Luigi GianaMarta IelminiMilano AnnaSani Emanuele And Daniele Zizolfi (Varese)Alberini GabrioBortolaso PaolaCazzamalli SaraCostantini Chiara Angela Di CaroParonelli ChiaraPiantanida Silvia And Marco Piccinelli (Varese Verbano)Alessandro Papalini Silva Veronica BarbantiD’ippolito ChiaraGozzi Mauro And Valentina Moretti (Reggio Emilia)Campese OrnellaCorbo Mariangela Lucia Di Capro Massimo Di GiannantonioFiori FedericaLorusso MarcoMancini ValerioMartinotti Giovanni And Daniela Viceconte (Chieti)Calandra CarmelaLuca Maria Maria Salvina Signorelli And Francesco Suraniti (Catania)Balzarro BeatriceBoncompagni GiancarloCaretto ValentinaEmiliani RobertaLupoli PasqualinoMenchetti MarcoRossi EugenioStorbini VivianaTarricone Ilaria And Laura Terzi (Bologna)Boso MariannaCatania Cristina Giuseppe De Paoli And Paolo Risaro (Pavia)Aspesi FloraBartoli FrancescoBava MattiaBono AdeleBrambilla GiuliaCarr`a GiuseppeCastagna GloriaLucchi SaraNava RobertoProvenzi MilenaTabacchi TommasoTremolada Martina And Enrica Verrengia (Monza) Michela Barchiesi And Maria Ginevra Oriani (Ancona) Monica Pacetti (Forlì)Aguglia AndreaFerro Maurizio And Lucio Ghio (Genova)Beneduce RossellaLaffranchini Laura Laura Rosa MagniRossi Giuseppe And Giovanni Battista Tura (Brescia)Addeo LelioBalletta Giovanni Elisa De Vivo Rossella Di Benedetto And Vincenzo Fricchione Parise (Avellino) Bernardo Carpiniello And Federica Pinna (Cagliari) Damiano Pecile (Mantova) Chiara Mattei (Fermo)Bonavigo Tommaso Elisabetta Pascolo FabriciPanarello SofiaPeresson Giulia And Claudio Vitucci (Trieste) Monica Pacetti (Forlì)And Stefania Strizzolo (Vicenza) Francesco GardellinCossetta EdoardoFizzotti Carlo And Daniele Moretti (Savona) Luana Di Gregorio And Francesca Sozzi (Trento) Giuseppe Colli And Daniele La Barbera (Palermo)Marche). And Sabrina Laurenzi (Civitanovasubject
Long-acting injectable antipsychoticPaliperidone palmitate 1-monthAripiprazoleAripiprazole monohydrateLong-acting injectable antipsychoticsPsychiatry and Mental healthPaliperidone PalmitateSchizophreniaHumansProspective StudiesSettore MED/25 - PsichiatriaBiological PsychiatryAripiprazole monohydrate; Long-acting injectable antipsychotics; Paliperidone palmitate 1-monthAntipsychotic Agentsdescription
In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-03-01 |